Ph.D., Immunology, The George Washington University summa cum laude
B.S., Biology, University of Mary Washington magna cum laude
United States Patent and Trademark Office
Dr. Markos is a registered patent agent in the firm's Biotechnology/Chemical Group, where she aids in the preparation and prosecution of U.S. and foreign patent applications, drafts non-infringement and invalidity opinions, conducts freedom-to-operate, due-diligence, and pre-launch clearance and patentability searches, prepares ANDA notice letters, detailed statements, and patent certifications, and provides litigation support. Dr. Markos's technical areas of expertise include immunology, oncology, tumor immunotherapy, biochemistry, and molecular and cellular biology.
Prior to joining Sterne Kessler, Dr. Markos completed a postdoctoral research fellowship at the National Cancer Institute, NIH. Her research involved the use of adoptive immunotherapy to study the role of apoptosis in cancer progression and tumor escape.
Dr. Markos's graduate research focused on the role of opioids in immune system development and function. Her studies revealed that opioids skew T helper cell development towards a type 2 phenotype leading to an asthmatic profile and susceptibility to infections.
Dr. Markos was a recipient of the NIH Fellows and Research Excellence Award, pre-doctoral and post-doctoral training grants from the NIH, a doctoral fellowship from The George Washington University, and a travel award from the Society on Neuroimmune Pharmacology.
Stewart TJ, Liewehr DJ, Steinberg SM, Greeneltch KM, Abrams SI. Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells. J Immunol. 2009 Jul 1;183(1):117-28.
Stewart TJ*, Greeneltch KM*, Reid JE, Liewehr DJ, Steinberg SM, Liu K, Abrams SI. Interferon Regulatory Factor-8 Modulates the Development of Tumor-Induced CD11b+Gr-1+ Myeloid Cells. J Cell Mol Med. 2009 Sept 13(9B):3939-50. (*Contributed equally to the study)
Greeneltch KM, Schneider M, Steinberg SM, Liewehr DJ, Stewart TJ, Liu K, Abrams SI. Host immunosurveillance controls tumor growth via IFN regulatory factor-8 dependent mechanisms. Cancer Res. 2007 Nov 1;67(21):10406-16.
Yang D, Thangaraju M, Greeneltch K, Browning DD, Schoenlein PV, Tamura T, Ozato K, Ganapathy V, Abrams SI, Liu K. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res. 2007 Apr 1;67(7):3301-9.
Stewart TJ, Greeneltch KM, Lutsiak ME, Abrams SI. Immunological responses can have both pro- and antitumour effects: implications for immunotherapy. Expert Rev Mol Med. 2007 Feb 7;9(4):1-20. Review.
Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J Immunol. 2006 Mar15;176(6):3374-82.
Greeneltch KM, Kelly-Welch AE, Shi Y, Keegan AD. Chronic morphine treatment promotes specific Th2 cytokine production by murine T cells in vitro via a Fas/Fas ligand-dependent mechanism. J Immunol. 2005 Oct 15;175(8):4999-5005.
Greeneltch KM, Haudenschild CC, Keegan AD, Shi Y. The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-alpha production. Brain Behav Immun. 2004 Sep;18(5):476-84.
Roberts AI, Devadas S, Zhang X, Zhang L, Keegan A, Greeneltch K, Solomon J, Wei L, Das J, Sun E, Liu C, Yuan Z, Zhou JN, Shi Y. The role of activation-induced cell death in the differentiation of T-helper-cell subsets. Immunol Res. 2003;28(3):285-93. Review.
Shi Y, Devadas S, Greeneltch KM, Yin D, Allan Mufson R, Zhou JN. Stressed to death: implication of lymphocyte apoptosis for psychoneuroimmunology. Brain Behav Immun. 2003 Feb;17 Suppl 1:S18-26. Review.
Sharma K, Wang RX, Zhang LY, Yin DL, Luo XY, Solomon JC, Jiang RF, Markos K, Davidson W, Scott DW, Shi YF. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther. 2000 Dec;88(3):333-47. Review.
Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler. If you are not already a client of Sterne Kessler, do not include any confidential information in this message.